EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: results from an open-label 6-month clinical trial



Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: results from an open-label 6-month clinical trial



Sleep 27(4): 674-682



Study Objectives: To assess the safety and efficacy of cabergoline in the treatment of idiopathic restless legs syndrome (RLS) patients. Design: Open-label intervention study for 26 weeks; no control group. Setting: 302 patients (73% women, aged 61 +/- 11 years) from 37 German neurologic outpatient departments and private practices. Intervention: Cabergoline was upwardly titrated over 4 weeks to individually optimized dosages. Median treatment duration was 181 days. The median daily dose of cabergoline was 1.5 mg. Measurements: Drug safety was assessed by adverse events; efficacy was evaluated with the RLS-6 and the International RLS Rating Scales. Results: In 48% of the study participants, investigators reported adverse events suspected to be drug related. Most adverse events were mild and transient and related to the gastrointestinal system (nausea: 16.6%) or the central nervous system (dizziness: 7.0%, headache: 4.6%). Premature dropout from the study occurred in 54 patients (17.9%), in 17 patients (3.0%) due to a drug-related adverse event. The severity of RLS symptoms at night, at bedtime, and during the day, as well as the International RLS Rating Scale total score improved during therapy. Satisfaction with sleep was increased (all P values < .001). In 5% of all patients, RLS symptoms worsened, and in a further 6.3%, response to therapy was poor. In 9 patients (3.0%) between 1 and 3 criteria for augmentation were noted. Conclusions: Long-term therapy with cabergoline is a safe and well-tolerated treatment option for the great majority of patients with idiopathic RLS. The treatment was efficacious both for nighttime and daytime symptoms in this indication and may carry a low risk of augmentation.

(PDF emailed within 1 workday: $29.90)

Accession: 012273600

Download citation: RISBibTeXText

PMID: 15283002



Related references

Treatment of idiopathic restless legs syndrome (RLS) with the D2-agonist cabergoline--an open clinical trial. Sleep 23(3): 349-354, 2000

Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet. Neurology 10(8): 710-720, 2011

One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome. Sleep Medicine 9(8): 865-873, 2008

Rotigotine transdermal patch improves quality of life in patients with idiopathic restless legs syndrome - 24 month results from a multi-national multi-centre, open-label, follow-up trial. 2007

Open-label study of the long-term efficacy and safety of pramipexole in patients with Restless Legs Syndrome (extension of the PRELUDE study). Sleep Medicine 9(5): 537-541, 2008

Treatment of Japanese restless legs syndrome patients with cabergoline: an open clinical preliminary trial. Internal Medicine 45(7): 453-455, 2006

A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome. Sleep Medicine 8(7-8): 742-752, 2007

Long-term safety of nebulized formoterol: results of a twelve-month open-label clinical trial. Therapeutic Advances in Respiratory Disease 2(4): 199-208, 2009

Long-term safety and efficacy of acotiamide in functional dyspepsia (postprandial distress syndrome)-results from the European phase 3 open-label safety trial. Neurogastroenterology and Motility, 2018

Efficacy and Safety of Long-term Treatment with Lurasidone in Older Adults with Bipolar Depression: Results of a 6 Month Open-label Study. American Journal of Geriatric Psychiatry 23(3): S170-S171, 2015

The safety of pergolide in the treatment of restless legs syndrome Results of a randomized long-term multicenter trial of pergolide in the treatment of RLS. Neurology 56(8 Supplement 3): A20, April 24, 2001

The safety of pergolide in the treatment of restless legs syndrome RLS Results of a randomized long-term multicenter trial of pergolide in the treatment of RLS. Sleep (Rochester) 24(Abstract Supplement): A17, April 15, 2001

The acute effect of a low dosage of pramipexole on severe idiopathic restless legs syndrome: an open-label trial. Neuropsychobiology 54(3): 195-200, 2007

Augmentation of restless legs syndrome after long-term treatment with pramipexole and cabergoline. Neurology 58(7 Supplement 3): A515, April 9, 2002

Long-term safety and efficacy of zafirlukast in the treatment of asthma: interim results of an open-label extension trial. Annals of Allergy, Asthma & Immunology 82(4): 361-369, 1999